Clinical trials: Metastatic Malignant Neoplasm
Advanced Breast Cancer, Metastatic Breast Cancer
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
The primary objective of Phase II is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive, unresectable locally advanced or metastatic breast cancer.
- Trial name
- NCT04924699
- Testing
- MRG002, Trastuzumab Emtansine for Injection
- Where
- 19 sites in China
- Volunteers
- 350 people
- Sponsor
- Shanghai Miracogen Inc.
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with…
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma)
- Trial name
- NCT01460134
- Testing
- CDX-1127
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Celldex Therapeutics
Gastric Cancer, Gastroesophageal Junction Cancer
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
- Trial name
- MAHOGANY (NCT04082364)
- Testing
- margetuximab, Retifanlimab, Tebotelimab
- Where
- 73 sites in United States, China and 7 more
- Volunteers
- 82 people
- Sponsor
- MacroGenics
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
This study is designed to evaluate the efficacy of pamiparib in participants with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency…
- Trial name
- NCT03712930
- Testing
- Pamiparib
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- BeiGene
Osteosarcoma
Phase II Study of Intravenous Rexin-G in Osteosarcoma
Rexin-G is a tumor-targeted gene medicine that is designed to seek out and destroy both primary tumors and metastatic cancers without the side effects of standard chemotherapy.
- Trial name
- NCT00572130
- Testing
- Rexin-G Dose 1, Rexin-G Dose 2
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Epeius Biotechnologies
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine (T-DM1) administered by intravenous (IV)…
- Trial name
- NCT00951665
- Testing
- paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Genentech, Inc.
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly (ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants…
- Trial name
- KEYLYNK-010 (NCT03834519)
- Testing
- Pembrolizumab, Olaparib, Abiraterone acetate
- Where
- 193 sites in United States, Argentina and 18 more
- Volunteers
- 793 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumors, Metastatic Solid Tumors
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
This study is an open-label, multicenter, first-in-human, Phase I, dose escalation study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of JSKN003 in subjects with advanced inoperable or metastatic…
- Trial name
- NCT05494918
- Testing
- JSKN003
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Alphamab (Australia) Co Pty Ltd.
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Non-Small Cell Lung Cancer
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
- Trial name
- NCT03273790
- Where
- Japan
- Volunteers
- 939 people
- Sponsor
- Bristol-Myers Squibb
Locally Advanced Unresectable or Metastatic Solid Tumors
A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours
This is a multicentre, open-label, first-in-human, phase 1/2 study of IBI133 in subjects with unresectable, locally advanced or metastatic solid tumours.
- Trial name
- NCT06170190
- Testing
- IBI133
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Prostate Cancer, Metastatic Prostate Cancer
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
This is an open-label, randomized, parallel group two-stage phase 1-2 study with an escalation and an expansion component. This study will evaluate an extended-release (ER) formulation of onapristone in patients with prostate…
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT02049190
- Testing
- onapristone, abiraterone
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Arno Therapeutics
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate…
- Trial name
- NCT06136650
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone acetate
- Where
- 330 sites in United States, Australia and 37 more
- Volunteers
- 1,314 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Cancer
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
The goal of this phase I-II clinical research study is to find the highest safe dose of XRP9881 and capecitabine that can be given in combination in the treatment of metastatic breast cancer in patients who have been previously…
- Trial name
- NCT00327743
- Testing
- larotaxel, capecitabine
- Where
- 2 sites in United States, France
- Volunteers
- 34 people
- Sponsor
- Sanofi
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
The study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor activity of CN202 in adult subjects with locally advanced or metastatic solid tumor or hematologic malignancies
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Hematologic Malignancies
- Trial name
- NCT05028478
- Testing
- CN202
- Volunteers
- 164 people
- Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
Cholangiocarcinoma, Urothelial Cancer
A Study of TAS-120 in Patients With Advanced Solid Tumors
This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120).
- Conditions
- Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors
- Trial name
- NCT02052778
- Testing
- Futibatinib
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 407 people
- Sponsor
- Taiho Oncology, Inc.
Neoplasms
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
The purpose of this early (pilot) clinical trial is to test the effects (both good and bad) of chemotherapy and adoptive immunotherapy with T cells engineered to recognize NY-ESO-1 peptide in patients with unresectable…
- Trial name
- NY-ESO-1 (NCT01343043)
- Testing
- NY-ESO-1(c259)T Cells, Fludarabine, Cyclophosphamide
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen
- Trial name
- NCT00715078
- Testing
- sipuleucel-T
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Dendreon
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.